

UC San Diego

UC San Diego Previously Published Works

Title

Structural elucidation of recombinant *Trichomonas vaginalis* 20S proteasome bound to covalent inhibitors

Permalink

<https://escholarship.org/uc/item/44c8k2c1>

Journal

Nature Communications, 15(1)

ISSN

2041-1723

Authors

Silhan, Jan

Fajtova, Pavla

Bartosova, Jitka

et al.

Publication Date

2024-10-01

DOI

10.1038/s41467-024-53022-w

Peer reviewed

Structural elucidation of recombinant *Trichomonas vaginalis* 20S proteasome bound to covalent inhibitors

Received: 22 September 2023

Accepted: 27 September 2024

Published online: 04 October 2024

 Check for updates

Jan Silhan ^{1,7}, Pavla Fajtova ^{1,2,7} ✉, Jitka Bartosova¹, Brianna M. Hurysz²,
Jehad Almaliti^{3,4}, Yukiko Miyamoto⁵, Lars Eckmann⁵, William H. Gerwick⁴,
Anthony J. O'Donoghue ^{2,6} ✉ & Evzen Boura ¹ ✉

The proteasome is a proteolytic enzyme complex essential for protein homeostasis in mammalian cells and protozoan parasites like *Trichomonas vaginalis* (*Tv*), the cause of the most common, non-viral sexually transmitted disease. *Tv* and other protozoan 20S proteasomes have been validated as druggable targets for antimicrobials. However, low yields and purity of the native proteasome have hindered studies of the *Tv* 20S proteasome (*Tv*20S). We address this challenge by creating a recombinant protozoan proteasome by expressing all seven α and seven β subunits of *Tv*20S alongside the Ump-1 chaperone in insect cells. The recombinant *Tv*20S displays biochemical equivalence to its native counterpart, confirmed by various assays. Notably, the marizomib (MZB) inhibits all catalytic subunits of *Tv*20S, while the peptide inhibitor carmaphycin-17 (CP-17) specifically targets β 2 and β 5. Cryo-electron microscopy (cryo-EM) unveils the structures of *Tv*20S bound to MZB and CP-17 at 2.8 Å. These findings explain MZB's low specificity for *Tv*20S compared to the human proteasome and demonstrate CP-17's higher specificity. Overall, these data provide a structure-based strategy for the development of specific *Tv*20S inhibitors to treat trichomoniasis.

Trichomonas vaginalis (*Tv*), a pear-shaped protozoan organism, is the etiological agent of trichomoniasis, the most widespread non-viral sexually transmitted disease (STD) worldwide^{1–3}. This parasite possesses a single flagellum, which enables its motility, as well as several hair-like structures called pili, facilitating its attachment to host cells. *Tv* has a complex cytoskeleton that gives it the ability to alter its shape and traverse host tissues. In women, *Tv* infection can cause vaginitis, while in men it can cause urethritis and prostatitis. Notably, this infection heightens the risk of transmission of HIV and other STDs in both sexes. Current treatment relies on 5-nitroimidazoles^{4,5}, however,

the emergence of resistant strains poses a significant public health threat due to the lack of alternative treatment options^{6,7}. Consequently, effective anti-parasitic compounds are urgently needed. Recently, the critical role of the proteasome in the survival of *Tv* was demonstrated, validating it as a potential drug target for treating trichomoniasis^{8–11}.

The proteasome is a large protein complex that plays a pivotal role in the degradation and homeostasis of cellular proteins^{12–15}. It consists of two main components: the 20S core particle and the 19S regulatory particle. The 20S core particle forms a cylindrical structure

¹Institute of Organic Chemistry and Biochemistry AS CR, v.v.i., Prague, Czech Republic. ²Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA. ³Department Pharmaceutical Sciences, College of Pharmacy, The University of Jordan, Amman, Jordan. ⁴Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, USA. ⁵Department of Medicine, School of Medicine, University of California San Diego, La Jolla, CA, USA. ⁶Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA. ⁷These authors contributed equally: Jan Silhan, Pavla Fajtova. ✉ e-mail: fajtova@uochb.cas.cz; ajodonoghue@health.ucsd.edu; boura@uochb.cas.cz

consisting of four stacked rings, comprised of two inner rings of seven different β subunits and two outer rings of seven different α subunits. Importantly, three of the β subunits, $\beta 1$, $\beta 2$ and $\beta 5$, have proteolytic activity and are therefore responsible for protein degradation^{16,17}.

Structural studies using yeast and mammalian proteasomes have greatly improved the understanding of the mechanisms of protein degradation by these enzymes, as well as their interactions with inhibitors and other proteins. To perform structural studies, highly pure and homogeneous samples are required. We and others have previously isolated proteasomes from parasites such as *Plasmodium falciparum* that are sufficiently pure for structural studies^{18,19} but efforts to isolate highly pure proteasomes from *Tv* were unsuccessful^{10,20}. One promising strategy to circumvent these technical limitations is to produce recombinant *Tv* proteasome. Archaeal 20S proteasomes, composed of homo-heptameric rings can be produced by co-expressing the two subunits in *E. coli*²¹. However, the tightly regulated biogenesis pathway of eukaryotic 20S proteasome makes expression in bacteria unfeasible²². The assembly of the human 20S proteasome involves the stepwise incorporation of 14 distinct protein subunits, $\alpha 1$ – $\alpha 7$ and $\beta 1$ – $\beta 7$, assisted by five dedicated chaperones. These chaperones consist of Ump-1 and the heterodimers, PAC1–PAC2 and PAC3–PAC4^{23,24}. The seven α subunits form the α -ring which then serves as a scaffold for the ordered incorporation of β subunits. After dimerization of two pre-assembled half-proteasomes, the final maturation step involves self-cleavage of the β subunit pro-peptides. These N-terminal extensions, present in immature β subunits, are believed to shield their proteolytic activity until formation of the entire 20S proteasome and may also contribute as scaffolds for proteasome assembly^{16,25}.

Following maturation, the $\beta 1$, $\beta 2$, and $\beta 5$ subunits contain a threonine residue as the N-terminal amino acid. This threonine residue can initiate a catalytic reaction through nucleophilic attack of the carbonyl carbon within the peptide backbone of the substrate. This reaction leads to cleavage of the protein or peptide substrates. The $\beta 1$, $\beta 2$, and $\beta 5$ subunits have distinct substrate specificity preferences and are generally considered to have caspase-like, trypsin-like, and chymotrypsin-like activities, respectively²⁶. These three subunits enable the proteasome to cleave a wide variety of substrates at distinct sites allowing the cell to efficiently degrade proteins and maintain cellular protein homeostasis^{27,28}.

Proteasome inhibitors bind to the proteasome, blocking its proteolytic activity and impeding protein degradation. This results in the accumulation of proteins within cells, ultimately triggering cell death. Proteasome inhibitors have been shown to selectively kill cancer cells and three (bortezomib, carfilzomib, and ixazomib) have been approved for treatment of multiple myeloma and mantle cell lymphoma²⁹. Additionally, proteasome inhibitors have recently been investigated as potential treatments for parasitic diseases, such as malaria^{19,30,31}, Chagas disease and leishmaniasis^{32–34}, with one molecule, LXE408, developed by Novartis Pharmaceuticals entering Phase II clinical trials for leishmaniasis in December 2022. These clinical studies in different parasites support our rationale for developing proteasome inhibitors to treat trichomoniasis.

Carmaphycin B is a marine cyanobacterial metabolite that was isolated from extracts of *Symploca* sp. collected from Curaçao³⁵. This compound is a potent inhibitor of the 20S proteasome from mammals, yeast, trematodes and protozoa^{30,35–37} and has potent cytotoxic activity in these cells. We have synthesized more than 100 analogs that exhibit a range of biological activities. Carmaphycin-17 (CP-17) is one analog that has been shown to have reduced cytotoxicity for human cells while exhibiting significant activity against *Tv*^{10,35}. Additionally, it has shown to be potent against metronidazole-resistant *Tv* strains¹⁰. In topical treatment studies of mice vaginally infected with the related trichomonad, *Trichomonas fetus*, CP-17 reduced parasite burden without noticeable adverse effects. These studies not only validated *Tv*

proteasome as a therapeutic target for trichomonacidal agents but also highlighted CP-17 as a starting point for further medicinal chemistry studies¹⁰.

Marizomib (MZB) is a natural product isolated from the marine bacterium *Salinispora tropica*³⁸. This non-peptidic proteasome inhibitor is currently in Phase III clinical trials for the treatment of various types of glioblastoma and stands out as the only proteasome inhibitor capable of readily crossing the blood-brain barrier^{39–41}. While MZB primarily targets the $\beta 5$ subunit of the 20S proteasome, it has been reported to also inhibit the $\beta 1$ and $\beta 2$ subunits at higher concentrations⁴². This ability to target multiple subunits of the proteasome may contribute to its potent anti-cancer activity. Compared to clinically approved proteasome inhibitors such as bortezomib and carfilzomib, MZB offers advantages including enhanced stability, bioavailability, and the potential for a broader range of anti-cancer activity. While MZB is too toxic for use as an anti-microbial drug, analogs of this molecule could be developed that are selective for *Tv* over mammalian cells.

In this study, we successfully employed the baculovirus expression system to generate recombinant *Tv*20S proteasome. Biochemical comparison with the native enzyme confirmed that all three catalytic subunits of the recombinant enzyme were functional, as they hydrolyzed three different subunit-specific fluorogenic substrates. A broad-spectrum activity-based probe covalently labeled the catalytic threonine from each subunit. Furthermore, we determined the structure of *Tv*20S in complex with MZB and CP-17. MZB was found to bind to six sites within *Tv*20S that corresponded to three subunits in each β -ring, albeit the electron density was insufficient to fully resolve its binding to the $\beta 5$ subunit. By comparison, CP-17 bound to four of six catalytic subunits, corresponding to $\beta 2$ and $\beta 5$ from each β -ring. These findings not only offer valuable insights into the structure and function of *Tv*20S proteasome but also shed light on the underlying molecular mechanisms of MZB and CP-17 inhibition.

Results

Expression of recombinant *Tv*20S

The genome of *T. vaginalis* G3 is available from trichdb.org and all 14 subunits of the *Tv*20S proteasome were identified by alignment with the human constitutive proteasome¹⁰ (Supplementary Fig. 1). From these analyses, we identified the putative $\beta 7$ subunit as A2F3X4 (UniProt ID) which in the human and yeast proteasome has been shown to be the last subunit incorporated into the α -ring/ β -ring half-proteasome^{43,44}. A sequence encoding a C-terminal twin-strep tag was added to the $\beta 7$ subunit (Supplementary Fig. 2) as this was expected to have minimal effect on the assembly of the proteasome complex. In addition, the *Tv* genome was searched for chaperone proteins with homology to PAC1–PAC2, PAC3–PAC4 or Ump-1 that are known to play a role in proteasome assembly in human cells^{22,45}. A homolog of human Ump-1 in the *Tv* genome (UniProt A2FJWO) with 21% sequence identity was identified (Supplementary Fig. 1) however, no homologs of PAC1–PAC2, PAC3–PAC4 were found.

Three baculoviruses were prepared, one bearing seven α subunit genes, one with seven β subunit genes, and a third with the Ump-1 chaperone gene (Fig. 1a). Insect cells were simultaneously infected with the three baculoviruses (Fig. 1b). The resulting recombinant protein complex was enriched from cell lysates on a streptavidin column and further purified by size exclusion chromatography. Only fractions containing catalytically active protein were selected as determined by assays with the Suc-LLVY-amc substrate (Fig. 1c). This substrate is cleaved by the $\beta 5$ subunits of *Tv*20S that are found on each of the β rings (Fig. 1d). A protein yield of ~1 mg per liter of cell culture was achieved.

Protein quality control

To assess the functional similarity of r*Tv*20S and native *Tv*20S (n*Tv*20S), both enzymes were incubated with the fluorescent inhibitor




Fig. 1 | Cloning, Recombinant Expression, and Purification of *Tv*20S Proteasome. **a** Cloning of three baculovirus vectors containing either 7 α -subunits, 7 β -subunits or Ump-1 from *T. vaginalis*. **b** Co-infection of Sf9 insect cells with the three baculoviruses for proteasome expression results in assembly of half proteasomes initially and then 20S proteasomes. The twin-strep tag is indicated by ~. **c** Final purification step of recombinant *Tv*20S using Superose 6 chromatography. Absorbance at 280 nm (blue line) and proteasome activity assessed using a fluorogenic substrate, Suc-LLVY-amc (grey bars). **d** Side and planar views of a 20S proteasome complex showing two β rings sandwiched between two α rings. Within

the β ring there are three catalytic subunits ($\beta 1$, $\beta 2$, $\beta 5$) located within the central core. **e** Denaturing gel comparing Me4BodipyFL-Ahx3Leu3VS-labeled *nTv*20S and *rTv*20S. The gel was imaged by silver staining and fluorescent scan. **f** Native-PAGE gel of the same proteins from panel **e**. The protein band in the red box was excised for proteomic studies. Gels were repeated independently three times with similar results. **g** Proteomics analysis of the excised band and searched against *T. vaginalis* and *S. frugiperda* proteomes. The blue shading correlates with peak intensity. Source data are provided in the Source Data file.

probe Me4BodipyFL-Ahx3Leu3VS. This probe irreversibly binds to the active sites of $\beta 1$, $\beta 2$, and $\beta 5$ subunits. We then analyzed the labeled enzymes on denaturing and native gels. Consistent with our previous findings on *nTv*20S²⁰, the probe strongly labeled the $\beta 2$ and $\beta 5$ subunits of both *rTv*20S and *nTv*20S, with weaker labeling of $\beta 1$ subunits (Fig. 1e). On a native gel both enzymes exhibited a similar molecular weight of approximately 690 kDa (Fig. 1f) although *rTv*20S appeared slightly larger. This could be attributed to the presence of a 28-amino acid Strep-tag on each $\beta 7$ subunit. This tag alters the overall isoelectric point (pI) of *rTv*20S and adds approximately 6 kDa in size.

Native *Tv*20S was isolated by sequential steps of ammonium sulfate precipitation, size exclusion chromatography (SEC), and anion exchange chromatography purification while *rTv*20S was affinity purified of a streptavidin column and then further refined by SEC. To assess the purity of both enzymes, we compared them using silver staining on native and denaturing gels. As shown in Fig. 1e, f, these analyses revealed the high purity of the *rTv*20S compared to *nTv*20S.

To understand the role of *Tv* Ump-1, we expressed *rTv*20S with and without this chaperone protein. In the absence of Ump-1, the

eluted fraction from the streptavidin column contained a higher ratio of half-proteasomes to full-proteasomes, indicating incomplete assembly. Interestingly, incubating these proteins for 72 h at room temperature partially rescued this defect (Supplementary Fig. 3). Additionally, $\beta 5$ subunit activity, measured using both the fluorogenic probe and substrate, was significantly weaker when Ump-1 was absent (Supplementary Fig. 3). The connection between Ump-1 and $\beta 5$ activity is supported by previous studies of the yeast proteasome where Ump-1 was shown to directly interact with the propeptide sequence of $\beta 5$ and properly orientate it between the $\beta 6$ and $\beta 7$ subunits⁴⁶. These findings collectively demonstrate that recombinant *Tv* Ump-1 functions as a critical chaperone, essential for the complete maturation and full activity of *rTv*20S.

Since *rTv*20S was expressed in *Spodoptera frugiperda* insect cells, we investigated the possibility of contamination with insect proteasome subunits. While the overall size difference allowed clear separation of *rTv*20S and the host cell proteasome (*Sf*20S) on a native gel (Supplementary Fig. 3), the potential incorporation of individual insect subunits into *rTv*20S remained a concern. To address this, the *rTv*20S

band from the native gel was excised and analyzed by proteomics. All 14 *Tv* subunits were identified and quantified when the mass spectrometry data was searched against the *Tv* proteome (Fig. 1g). Additionally, the data was searched against the insect proteome. While six insect subunits were detected, their abundance was significantly lower (>100-fold) than the equivalent *Tv* subunits (details are provided in the Source Data file). These quality control measures demonstrate that *rTv20S* is a highly pure and enzymatically active enzyme complex, suitable for further biochemical and structural studies.

Biochemical characterization of *rTv20S*

We next compared the catalytic activity of the *rTv20S* and *nTv20S* using a combination of inhibitors and fluorogenic substrates. As revealed in Fig. 1e, the fluorescent probe, Me4BodipyFL-Ahx3Leu3VS, binds to all three catalytic subunits. Preincubation of the proteasome with irreversible-binding inhibitors prevents labeling with the probe. When *rTv20S* and *nTv20S* were incubated with 50 μ M of CP-17 followed by the probe, the β 2 and β 5 subunits were no longer labeled (Fig. 2a). When the same proteins were incubated with 50 μ M MZB none of the catalytic subunits were labeled with the probe. These data reveal that CP-17 binds to β 2 and β 5, while MZB binds to all three catalytic subunits (Fig. 2b). In addition, these studies show that *rTv20S* and *nTv20S* have the same inhibition profile when using Me4BodipyFL-Ahx3Leu3VS as a reporter of subunit targeting. As a control, human 20S (*Hs20S*) was preincubated with CP-17 and MZB prior to labeling with the probe. CP-17 completely inhibited β 5, partially inhibited β 2 and did not inhibit β 1, while MZB targeted all three subunits.

The functionality of *rTv20S* was further compared to *nTv20S* through enzyme kinetic assays using subunit-specific fluorescent substrates²⁰. Using a concentration range of 2 to 250 μ M for the β 2 and β 5 substrates and 10 to 1250 μ M for the β 1 substrate, the specific activity was indistinguishable between the two enzymes, and the catalytic rate constant (k_{cat}) and Michaelis constant (K_M) were calculated for all three subunits of *rTv20A* and *nTv20S* (Fig. 2c) to reveal that these enzymes were equivalent.

Finally, we used fluorogenic assays to show that the relative activity of *nTv20S* and *rTv20S* in the presence of inhibitors is similar. Using the β 5 and β 2 substrates, the activity of both enzymes was reduced to comparable levels following pre-incubation with 50 μ M CP-17 or MZB (Fig. 2d). For the β 1 substrate, MZB reduced activity for both enzymes to comparable levels. However, CP-17 activated the β 1 activity of *nTv20S* by 200% but activated *rTv20S* by only 120%. Although activation of β 1 in the presence of β 5 and β 2 inhibitors was observed previously for *nTv20S*²⁰ it is unclear why this occurs. Our follow-up studies revealed that β 1 activation of *rTv20S* in the presence of CP-17 is independent of the substrate concentration used in the assay with activation ranging from 120% to 160% (Supplementary Fig. 4). In summary, these probe-labeling and enzyme activity assays revealed that *rTv20S* is enzymatically identical to *nTv20S* and therefore, validates the use of the recombinant enzyme for biochemical and structural studies.

Overall structural characterization of the *Tv20S* proteasome

To obtain atomic models of the *Tv20S* proteasome structure with bound inhibitors, we mixed *rTv20S* with a 50-fold excess of CP-17 or MZB and subjected it to cryo-EM. Initial data analysis revealed that the recombinant sample with MZB contained a significant amount of unassembled proteasome. During the 2D classification of the collected dataset, only 2% of the particles corresponded to the assembled 20S proteasome, while the remaining ring particles mostly consisted of half-proteasome complexes made up of a single α and β ring. The low abundance of full proteasomes was not due to inhibitor-dependent disassembly of proteasome (Supplementary Fig. 3e) and therefore may have occurred during the grid set-up.

We were able to obtain a 2.86 Å cryo-EM map of the *Tv20S* proteasome, which was used to build the initial atomic model of the *rTv20S* with MZB; PDB ID: 8OIX. For *rTv20S* bound to CP-17, we performed a second round of gel filtration to enrich the larger 20S proteasomes over the half-proteasomes. Each fraction was then analyzed for the presence of fully assembled *Tv20S* using negative-stain electron microscopy. This procedure improved yields so that approximately 80% of all particles could be assigned to the fully assembled *Tv20S* proteasomes. The data collected from this sample allowed the cryo-EM reconstruction and determination of the atomic structure of *Tv20S* with CP-17; PDB ID: 8POT.

The initial *Tv20S* atomic model was built by leveraging AlphaFold models, which were superimposed onto the existing 20S proteasome structure of *Leishmania tarentolae* 20S proteasome (PDB ID: 7ZYJ)⁴⁷ and fitted to the cryo-EM maps. Subsequently, the model was refined and rebuilt based on these maps. Unsurprisingly, *Tv20S* exhibits a shape and fold consistent with the characteristic overall structure of 20S proteasomes. *Tv20S* displays C2 symmetry, with the two sets of 14 subunits arranged in the conventional ring configuration of α 1– α 7, β 1– β 7 / β 1– β 7, α 1– α 7. Despite the homology among the individual chains between *Tv* and *L. tarentolae* 20S proteasome variations in their arrangement were discovered. The overall fold of the *Tv20S* proteasome somewhat differs from other proteasomes with known structures (e.g., RMSD = 2.729 Å for C α atoms in structural alignment with the *L. tarentolae* 20S proteasome). It is worth noting that, in these structures, the *Tv20S* sequence (3167 residues) was mapped onto the cryo-EM maps, achieving 96.8% coverage for *Tv20S*/MZB and 96.6% for *Tv20S*/CP-17 structures. This includes well-defined regions, such as the active site pockets, which allowed for the modeling of inhibitor molecules in both structures.

Structure of active sites of the catalytic subunits β 1, β 2, and β 5 bound to inhibitors

All three active sites in *Tv20S* are defined by a conserved catalytic triad Thr1, Asp17, and Lys33²⁶. In addition, other well-conserved residues, such as Asp168, Ser131, and Ser170 in β 1, are predicted to be required for efficient catalysis and active site structural integrity⁴⁸. In the *Tv20S*-MZB dataset, the electron map within the β 1 active site exhibited clear density extending beyond Thr1, providing sufficient coverage for the inhibitor MZB. As a result, the atomic model of MZB was successfully built and fit accurately into the cryo-EM map (Supplementary Fig. 5). Conversely, no density was observed within the β 1 active site for CP-17 in the other dataset. This is consistent with the biochemical data (Fig. 2d), which demonstrated that MZB inhibits β 1 activity while CP-17 does not.

The second active subunit, β 2, can accommodate both MZB and CP-17 inhibitors in its active site, as clearly shown by the cryo-EM maps of those regions (Supplementary Figs. 5 and 6). MZB adopts a conformation like that observed in the β 1 site. In both cases, the cyclohexenyl moiety of MZB and the phenyl residue of CP-17 occupy a deep pocket that is shared by several residues, including Lys33, and a loop composed of Ala46, Ala49, Glu31, and Asn52 (Fig. 3f). This pocket is commonly referred to as the S1 pocket of the enzyme because it serves as the binding site for the P1 amino acid of the substrate, which is on the N-terminal side of the scissile bond. For CP-17, the α,β -epoxyketone group is covalently bound to Thr-1 forming a morpholino derivative. Beyond the S1 pocket, the P2 tryptophan of CP-17 interacts with the β 2 active site through its indole ring that resides on the hydrophilic ridge of the shallow S2 pocket, whereas the indole ring of the P3 tryptophan is buried and fits well within the deep S3 pocket. The S3 site is characterized by the presence of aliphatic chains, including Val28 and six alanine residues (Ala20, Ala22, Ala27, Ala124, Ala130, Ala132). Additionally, Glu31 and Asp126 line the S3 pocket, creating an acidic environment. The N-terminal capping group of CP-17 is a hexyl chain, which is orientated in a shallow S4 pocket.




Fig. 2 | Biochemical and enzymatic characterization of recombinant *Tv*20S. **a** Schematic representation of active sites during inhibition by MZB or CP-17, followed by visualization through fluorescent Me4BodipyFL-Ahx3Leu3VS probing. The inhibitor is depicted binding to specific active sites, thereby blocking enzymatic activity. Subsequent visualization techniques provide insights into the binding interaction and potential conformational changes induced by the inhibitor. **b** rTv20S, nTv20S and Hs20S were first incubated for 1 h with 50 μM CP-17 or 50 μM inhibitor or the solvent control, DMSO, and then incubated with 2 μM

Me4BodipyFL-Ahx3Leu3VS for 16 h, followed by fractionation on a denaturing gel and fluorescence imaging at 470 nm excitation and 530 nm emission. The experiment was repeated independently three times with similar results. 'ST' stands for the molecular weight ladder. **c** Comparison of dose response curves for nTv20S and rTv20S with K_M and k_{cat} values indicated. Assays were performed in triplicate, with each dot representing the mean of 3 technical replicates. **d** Comparison and validation of inhibitor specificity using the indicated subunit-specific *Tv*20S proteasome substrates. Assays were performed in technical replicates ($n = 3$).

In the catalytic site of $\beta 5$, electron density corresponding to MZB was observed in the cryo-EM map. However, unlike the observations made for the $\beta 1$ and $\beta 2$ sites, the MZB in $\beta 5$ was not sufficiently defined to allow for a satisfactory fit. Even though we found that MZB inactivates the $\beta 5$ catalytic activity, it could not be included in the final model. In contrast, the density of CP-17 in the $\beta 5$ site was clearly defined. The ligand was positioned in a highly similar conformation to that observed in the $\beta 2$ site (Fig. 3). The α, β -epoxyketone group was covalently bound to Thr-1 and the P1 phenylalanine is located in the S1 pocket, which is lined with Lys33, Ala46, and Ala69. In contrast to the $\beta 1$ and $\beta 2$ sites, the S1 of $\beta 5$ harbors Val31 and Met35. Moving forward, the P2 indole ring is

positioned on the ridge of S2, formed by the loop between Ala46 and Ala49, and is enclosed by Ser96. The P3 indole is anchored in the relatively deep S3 pocket, defined by π - π interaction with the residue Phe27. Finally, the hexyl group of CP-17 sits in a well-defined shallow pocket formed by the hydrophobic parts of four residues belonging to the neighboring $\beta 6$ chain (Tyr116, Asp136, Pro137, and Val138).

Comparison of the active proteasome sites of human and *T. vaginalis* for improved design of selective inhibitors

At first glance, the overall fold of the human constitutive proteasome and *Tv*20S appears very similar. However, upon structural alignment,




Fig. 3 | Cryo-EM structures of *Tv20S* bound to inhibitors. Processing of the cryo-EM datasets for **a** *Tv20S* bound to MZB and **f** CP17. The electron maps highlight the inhibitors in the active sites (**b**, **g**), shown as green mesh, while the catalytic subunits are depicted in different colors ($\beta 1$ yellow, $\beta 2$ cyan, and $\beta 5$ magenta). MZB was observed only in the catalytic sites of $\beta 1$ and $\beta 2$ (**b–e**), while CP-17 was observed

only in the catalytic sites of $\beta 2$ and $\beta 5$ (**g–j**). Both inhibitors were covalently bound to Thr1 as detailed for MZB in panels **b–e**) and for CP-17 in panels **g–j**. Amino acid residues within a reach of non-covalent interactions (up to 4 Å) are shown as sticks. More detailed interactions between inhibitors and active site pockets are shown in Supplementary Figs. 12–14.

the overall root mean square deviation (RMSD) is calculated to be 2.638 Å (Fig. 4a), which is higher than anticipated given the conservation of individual subunits. This disparity can be attributed to the slightly different packing of *Tv20S*, leading to less-than-optimal overall alignment. When aligning the individual subunits, the RMSD values decrease accordingly as the aligned sequences exhibit a range of 25–51% amino acid identity, with conserved regions in the active sites (Supplementary Table 1). Despite this relatively high sequence identity, the fine structural variances within the active site pockets present

opportunities for designing selective inhibitors targeting *Tv20S* over human 20S, as illustrated by CP-17, which inhibits the *Tv20S* $\beta 5$ subunit with a 10-fold higher potency than the equivalent subunit of the human constitutive proteasome¹⁰. In the human 20S proteasome, several amino acids pose steric hindrances, resulting in clashes when hypothetically positioning the CP-17 inhibitor within the active sites based on the alignment of *Tv20S* and the human proteasome.

In the $\beta 2$ active site, many of the residues are conserved but in the S3 pocket where the second indole ring is positioned, the human 20S




Fig. 4 | Structural comparison of *Tv*20S and human 20S. The panel **a** comparison of human (orange) and *T. vaginalis* (light blue) 20S proteasomes. The further panels (**b–d**) show structural overlay of human 20S and covalent inhibitor CP-17 (blue sticks) in the active site pockets of β 2 (panels **b, c**) and β 5 (panels **d, e**) of *Tv*20S. The residues responsible for major structural differences in these active sites are shown as sticks (human-orange, *Tv*20S β 2 cyan, and β 5 magenta, and other subunits shown in white). The predicted clashes between CP-17 and amino acids from human 20S are encircled with dashed lines. In panels **b, c**, Met131 of human β 2

is in clash with one of the indole rings of CP-17, whilst in *Tv*20S this moiety is accommodated in a deep hydrophobic pocket formed by Ala132 and Ala130. Similarly, in panels **d, e**, the pocket formed by Met45 of *Tv*20S β 5 allows sufficient space for the phenyl ring of CP-17. In this location, human β 5 Met45 is pushed by Ile35 towards the active site, forming a potential barrier for CP-17. The further detailed views highlighting the differences between human 20S and *Tv*20S-CP-17 in particular are shown in Supplementary Fig. 15.

contains bulkier residues, such as Met131 and Ser122, in contrast to the significantly smaller alanine residues found at these positions in the *Tv*20S β 2 site (Fig. 4b, c). The S3 pocket of the β 5 subunit of *Tv*20S contains Phe27, which forms a favorable π - π interaction with the indole ring and represents the sole significantly different residue in this site. Conversely, the S1 pocket of the human active site contains Met45 and Ile35, which may obstruct the binding of the phenyl ring (Fig. 4d, e). It is plausible that Met45 from *Tv*20S exhibits greater mobility, moving away from the approaching ligand and not being hindered by Ile35, while the π - π interaction with Phe27 enhances the binding of the ligand in the case of *Tv*20S proteasome. This differential binding mechanism allows CP-17 to bind to the β 5 site with greater selectivity compared to the human enzyme.

Furthermore, upon exploring the surfaces and binding interfaces of all the active sites in *Tv*20S and human 20S proteasomes, it becomes evident that the β 2 and β 5 active sites, along with their respective S1 and S3 pockets, exhibit significant differences in shape. These differences offer additional opportunities for further inhibitor design (Fig. 5). Although the distinct amino acid composition and slight differences in the arrangement of the β 2 compared to β 5 active sites pose challenges for the design of selective β 2 inhibitors.

Discussion

While structural and enzymatic studies are crucial for identifying exploitable differences between parasite and human proteasomes, research has been hampered by difficulties in acquiring sufficient enzymes. Isolating proteasomes from intracellular parasites like *Plasmodium* and *Babesia* is challenging due to their complex cultivation needs. Even for parasites with easier culturing, such as *Trypanosoma*, *Leishmania*, and *Trichomonas*, obtaining highly purified enzyme remains difficult. For instance, our recent work revealed copurification of actinin and a legumain protease with native *Tv*20S^{10,20}.

This study presents a powerful solution, utilizing a heterologous expression system to overcome purity and yield limitations. We report a pathogen proteasome expressed in an insect cell line. Three separate baculoviruses containing the *Tv* genes for γ α , γ β , and Ump-1 were used to infect Sf9 cells, resulting in the production of fully functional recombinant *Tv*20S. This was also confirmed by the observation of fully assembled *Tv*20S with the C-terminus of the β 7 subunit, that is known to stabilize nascent 20S⁴⁹, properly inserted into the space between β 1 and β 2 of the opposing half proteasome (Supplementary Fig. 7). *Tv*20S was an ideal candidate due to our existing in-depth understanding of its catalytic subunits and the ability to directly compare the native and recombinant enzymes³⁰. Maintaining consistency between native and recombinant *Tv*20S in inhibitor interactions is critical to avoid misinterpretations in structure-activity relationship studies.

The successful expression of *Tv*20S using the baculovirus system suggests broad applicability to proteasomes from other pathogens. For intracellular parasites like *Plasmodium falciparum* and *Babesia divergens*, parasitemia levels are often low, and therefore obtaining high yields of enzyme is difficult^{30,31,50}. Many pathogens don't replicate in culture at all, necessitating harvest from invertebrate animals. For instance, the life cycle of *Schistosoma mansoni* requires both freshwater snails (intermediate host) and hamsters. We previously isolated the 20S proteasome from *S. mansoni* worms, demonstrating its potential as a drug target³⁶. Therefore, a method for expressing recombinant 20S proteasomes from various pathogens would significantly aid biochemical and structural studies.

Our purified recombinant *Tv*20S was used to determine two structures in complex with different inhibitors. Despite the overall structural conservation of proteasomes across all life forms (archaea to humans), *Tv*20S exhibits some key variations. Like other eukaryotes, *Tv*20S possesses four stacked heptameric rings. The outer rings




Fig. 5 | Surface detail of comparison of *Tv20S* and human 20S active sites. *Tv20S* surface is in light blue, panels a–f, and its Thr1 residue is shown as blue sticks. *Hs20S* proteasomes is in light yellow, panels g–i, and its Thr1 is shown as orange sticks. MZB and CP-17, shown as blue sticks, are displayed in the human active site pockets using a structural overlay from Fig. 4. The clashes are encircled with a red dotted line. In panel h, Met131 of human $\beta 2$ forms shallower binding pocket in this region

whilst a similar elevation of active site pocket is observed formed by Met45 from human $\beta 5$. In this location, human Met45 ($\beta 5$) in this ligand-free structure is pushed by Ile35 towards the active site. Please refer to Supplementary Fig. 15 for more structural detail highlighting these differences including the architecture of human Glu22 ($\beta 2$), and Glu106 ($\beta 3$).

consist of α subunits for scaffolding, while the inner rings contain the catalytic β subunits. Unlike archaea where these subunits are identical, *Tv20S* β subunits have diverged while maintaining high sequence similarity with other eukaryotic pathogens (Supplementary Fig. 1). Using sequence homology to human counterparts, we identified each *Tv20S* α and β subunit, along with a homolog of human Ump-1 in the *Tv* genome. Functional assays confirmed the activity of all three catalytic subunits as they were labeled by an activity-based probe and could cleave previously established substrates.

Furthermore, we investigated the effect of the proteasome inhibitor CP-17 on both native and recombinant *Tv20S*. Interestingly, CP-17 inhibited the $\beta 2$ and $\beta 5$ subunits in both enzyme forms, while $\beta 1$ activity was surprisingly enhanced. These findings demonstrate a high degree of consistency between the native and recombinant enzyme in inhibitor interactions, bolstering confidence in the recombinant *Tv20S* as a valuable tool for future drug development endeavors.

Data from our structural studies reveal how MZB and CP-17 inhibit *Tv20S* and provide a structural basis for the development of more specific inhibitors. For instance, the arrangement of the S2 substrate binding pocket in the $\beta 1$ subunit prevents interactions with CP-17. This binding pocket contains Pro27, Gln112 and Gln127. The two Gln residues are responsible for narrowing the binding groove which prevents binding of the P2 indole ring of CP-17. The active site pocket that accommodates the cyclohexenyl group of MZB appears to be too shallow to accommodate the phenyl group of CP-17. In the overlay of

these $\beta 1$ and $\beta 2$ subunits, residue Arg45 of the $\beta 1$ pocket is too close to phenyl group (2.4 Å) (Supplementary Figs. 8 and 9).

Our studies revealed that MZB inhibits the three catalytic subunits of *Tv20S*, therefore binding to all six active sites. In contrast, CP-17 selectively inhibits $\beta 2$ and $\beta 5$, leaving two active sites available. Interestingly, enzyme activity assays showed that CP-17 inhibition of $\beta 2$ and $\beta 5$ subunits led to increased substrate cleavage by the remaining $\beta 1$ subunit (Fig. 2d and Supplementary Fig. 4). To investigate this unexpected activity increase, we compared the structures of the $\beta 1$ subunit bound to MZB and unbound in the CP-17 complex (Supplementary Fig. 9). We hypothesized that the unbound $\beta 1$ subunit might have a conformation that facilitates substrate access. However, both structures (empty and MZB-bound) displayed identical shapes and volumes (Fig. 5, d), suggesting a structural change was not responsible for the increased activity. Therefore, we propose that the higher activity is due to increased substrate concentration at the $\beta 1$ subunit. With $\beta 2$ and $\beta 5$ blocked by CP-17, the substrate has only $\beta 1$ available for interaction, leading to a higher observed activity compared to the uninhibited enzyme.

CP-17 demonstrates promising potential as a candidate for trichomoniasis by targeting *Tv20S* proteasome active sites with high potency and selectivity. However, the structural knowledge gained here will facilitate the design of now analogs with even greater potency and selectivity. An ideal inhibitor would, additionally, bind the $\beta 1$ site of *Tv20S* but not the $\beta 1$ subunit of the human proteasome. Future CP-17 analogs could exploit the presence of Cys46 in *Tv20S*'s $\beta 1$ S1 pocket

(Supplementary Fig. 8a) to form a covalent bond with this residue, potentially enhancing selectivity for Tv20S. This is particularly attractive because the human 20S proteasome lacks Cys46 (Supplementary Fig. 1).

In summary, recombinant proteasome expression via a baculovirus system offers a powerful tool for studying parasite proteasomes. Despite the overall structural similarity, key variations in Tv20S compared to human 20S enable selective targeting. Inhibitor studies with Tv20S revealed a mechanism for increased β 1 activity with CP-17, and identified Cys46 in the β 1 subunit as a promising target for specific drug development.

Methods

Cloning, expression, and protein purification

The cDNA sequences of the 14 proteasome subunits and the assembly chaperone (maturation factor) Ump-1 were identified for the *T. vaginalis* G3 strain on TrichDB by aligning them with human proteins (Supplementary Fig. 1). Required genes were *E. coli* codon-optimized, synthesized (Azenta) and cloned into three separate pACEBac1 vectors by restriction cloning (Supplementary Fig. 2). The plasmids were transposed to DH10EmBacY cells (Geneva Biotech) and the baculoviruses and protein expression was performed in Sf9 insect cells (Thermo Fisher, catalog number #11496015), according to the manufacturer's instructions.

The expression of the 20S proteasome was performed in the presence or absence of the Ump-1 chaperone to understand its importance. Sf9 cells were collected after 72 h postinfection and centrifuged for 15 min at 2,000 \times g and the pellet was diluted in Buffer A (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA) at a volume corresponding to 4-times the volume of the pellet. Cells were lysed by sonication and the lysate was cleared by centrifugation at 30,000 g for 20 min. The cleared lysate was loaded onto tandem Streptactin XP columns (QIAGEN), equilibrated in Buffer A. Upon extensive washing with Buffer A, protein was eluted in the same buffer supplemented with 50 mM biotin. Proteasome-containing fractions were pooled, concentrated using ultrafiltration (Amicon) and loaded onto a Superose 6 Increase 10/300 gel filtration column (GE Healthcare) equilibrated with 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA. Fractions of 0.5 ml were obtained and assayed for protease activity. Enzymatically active fractions were pooled and concentrated to 1 mg/ml. The native Tv20S proteasome was purified from frozen pellets of *Tv* parasites as described previously²⁰.

Proteasome activity and inhibition assays

The β 5 proteolytic activity of the 20S proteasome was measured in insect cell extracts and in fractions isolated from chromatography columns using the fluorogenic substrate, Suc-LLVY-amc (Cayman Chemical). For enzyme characterization studies, substrates specific for Tv20S β 1, β 2, and β 5 subunits, namely Ac-RYFD-amc, Ac-FRSR-amc, and Ac-GWYL-amc, were used as described previously²⁰. These substrates were custom-synthesized by GenScript, NJ. For inhibition studies, 1 μ M recombinant Tv20S was incubated with 50 μ M MZB, 50 μ M CP-17 inhibitor, or 0.5% DMSO (vehicle control) for 1.5 h at room temperature. The inhibition of individual Tv20S subunits was confirmed using the subunit specific fluorogenic substrates. Kinetic assays in 384-well plates were performed using 4.4 nM recombinant Tv20S (rTv20) or enriched native Tv20S (nTv20S) in 50 mM HEPES pH 7.5 with 80 μ M of Ac-RYFD-amc, 25 μ M of Ac-FRSR-amc, and 25 μ M of Ac-GWYL-amc, in a final volume of 8 μ L per well. All assays were performed in triplicates in 384-well black plates (Nunc) at 37 °C using a Synergy HTX Multi-Mode Microplate Reader (BioTek, Winooski, VT) with excitation and emission wavelengths of 360 and 460 nm, respectively.

Gel-based active site probing

Protein lysates, nTv20S, rTv20S, Hs20S, and 20S-inhibitor complex were diluted with 50 mM HEPES pH 7.5 then mixed with 2 μ M Me4BodipyFL-Ahx3Leu3VS (R&D Systems #1-190). After probe addition, samples were incubated at room temperature for 16 h. For denaturing gels, samples were mixed with 4X Bolt LDS sample buffer (Thermo Fisher Scientific) containing 250 μ M dithiothreitol, heated at 100 °C for 5 min, and loaded onto a NuPAGE 12% Bis-Tris gel (Thermo Fisher Scientific, P/N). PageRuler Plus pre-stained protein ladder (Thermo) was included on each gel. Gels were run with 1X MOPS SDS buffers (Invitrogen) at 130 V. For native gels, samples were mixed with 2X Novex Tris-glycine native sample buffer and loaded onto NuPAGE 3-8% Tris-glycine gels (Invitrogen) with NativeMark unstained protein standard (Thermo Fisher Scientific, P/N 57030). Gels were run at 100 V with Novex Tris-glycine running buffer (Invitrogen). All gels were imaged on Bio-Rad ChemiDoc XRS+ at 470 nm excitation and 530 nm emission for Me4BodipyFL-Ahx3Leu3VS probe visualization and silver stained.

Native gel digestion and desalting

After the native gel was silver stained, the band with recombinant proteasome ($n=1$) was excised, sliced into smaller fragments, and washed three times with 25 mM NH_4HCO_3 , 50% acetonitrile for 10 min each time. Next, the band pieces were dried completely in a Savant Speed Vac Plus AR (Thermo Fisher Scientific). Reduction and alkylation were performed by adding a mixture of 10 mM TCEP and 25 mM iodoacetamide in 25 mM NH_4HCO_3 to the gel pieces and this reaction proceeded in the dark for 1 h, followed by a 25 mM NH_4HCO_3 wash and subsequent 25 mM NH_4HCO_3 , 50% acetonitrile wash to dehydrate the gel. The sample was then dried in a Savant Speed Vac Plus AR and 12.5 ng/ μ L trypsin in 25 mM NH_4HCO_3 was added. The sample was incubated at 4 °C before being covered in 25 mM NH_4HCO_3 where the digestion proceeded at 37 °C for 20 h. The supernatant was transferred to a clean tube and the remaining peptides were extracted from the gel by the addition of 50% acetonitrile, 5% formic acid. The extracted digest was dried and resuspended in 0.1% formic acid before C18 ZipTip desalting. A C18 column was washed with methanol and spun for 45 s at 3500 \times g. The column was equilibrated with 0.1% formic acid in 50% acetonitrile followed by 0.1% formic acid in water. The sample was loaded onto the column and spun for 2 min at 2000 \times g. It was then washed with 0.1% formic acid then eluted from C18 with 50% acetonitrile, 0.1% formic acid by spinning at 3500 \times g for 45 s. The sample was dried in a Savant Speed Vac Plus AR and stored at -80 °C for 1 week prior to preparing it for mass spectrometry.

LC-MS/MS

The sample was redissolved in 0.1% formic acid prior to LC-MS/MS injection. Chromatography was performed on an Easy-nLC 1200 (Thermo Fisher Scientific), with a 75 μ m i.d. PicoFrit (New Objective, Woburn, MA) column packed with 1.9 μ m AQ-C18 material (Dr. Maisch, Germany) to 50 cm in length. Peptides were separated at 50 °C over 46 min run which consisted of 6% solvent B at 1 min to 30% B in 21 mins, 72% B by 30 min, 90% by 31 min, and finally 60% B until 46 min. Mass spectrometry was performed on a Orbitrap Eclipse with ETD and PTCR (Thermo Fisher Scientific). The scan range was 350–1800 m/z , resolution of 60,000, and a 50 ms maximum injection time. The top 8 scans were selected for MS2. MS/MS spectra were analyzed in PEAKS Studio (v 8.5) software (Bioinformatics Solutions Inc.). MS2 data were searched against the *T. vaginalis* and *S. frugiperda* proteome (UniProt taxon ID: 412133, ID: UP000829999). A precursor tolerance of 20 ppm and 0.01 Da was defined. Trypsin digestion was specified. The data can be found at <ftp://massive.ucsd.edu/v07/MSV000094569/> or at proteome Xchange: PXD051584.

Preparation of cryo-EM grids and data acquisition

Recombinant purified *Tv20S* (1.4 μM) was mixed with 1.25 mM of either MZB or CP-17 to achieve a final concentration of 50 μM inhibitor. The mixture was prepared in a solution of 50 mM HEPES pH 7.5 and incubated at room temperature for 1 h. After the incubation period, the sample was cooled on ice. Simultaneously, the cryo-EM Quantifoil R2/1 300-mesh copper grids (EM Sciences, Prod. No. Q350CR1) were glow discharged at 15 mA for 30 seconds to enhance their hydrophilicity. The proteasomes-inhibitor complex (4 μL) at a concentration of 1 mg/ml was transferred to the grid. The grids were blotted at -5 power for 5 s in FEI Vitrobot Mark IV (Thermo Fisher Scientific) at 4 $^{\circ}\text{C}$ and 100% humidity and immediately frozen in liquid ethane. Immersion freezing and screening of cryo-EM data and all data acquisition were performed at the Umeå Core Facility for Electron Microscopy, Sweden. Screening was performed using a 200 kV Glacios system (Thermo Fisher Scientific) equipped with a Falcon 4i direct electron detector. 7983 images of *Tv20S* with MZB and 10,037 images of *Tv20S* with CP-17 were acquired with a pixel size of 0.7 \AA with an exposure of 40 electrons per \AA^2 on Titan Krios (Thermo Fisher Scientific) at 300 kV using a Falcon 4i direct electron detector. Data collection was performed using the EPU v 3.0.0 data collection software (Thermo Fisher).

Cryo-EM imaging

The data for *Tv20S* complexed with MZB was processed using cryoSPARC (v4.0.1). Images were imported and corrected using default settings for patch motion and patch contrast transfer function (CTF). Particles were selected using a blob picker (with a particle search size of 190 \AA), extracted with a box size of 440 pixels, and classified using a 2D classification job. For *Tv20S*-MZB initial 100 2D classes were sorted using 2D classification. Particles and exposures were reduced to 6,135 micrographs by manual curation. Subsequent 2D classification revealed that of the 916,422 good particles, only 2% of the 2D classes contained the entire proteasome. After several rounds of 2D classification to remove unwanted particles, the subset of 13,933 particles (side views only) was used for an ab initio reconstruction and further homogeneous refinement. The resolution changed from 2.79 \AA to 2.86 \AA during 3D classification and removal of poor 3D classes and further reiterations including 2D classifications. We have observed rather a large gap between the unmasked-calculated resolution (3.73 \AA with the 0.143 threshold and 6.91 \AA with the 0.5 threshold). The C2 symmetry was applied in 3D homologous refinement steps for the generation of the final model. The cryo-EM map (GSFSC) achieved a final resolution of 2.86 \AA , utilizing 14,257 particles.

The cryo-EM 3D map for *Tv20S* complexed with CP-17 was generated in a similar manner. Images were imported in small batches and then pooled, motion-corrected, and CTF-corrected in four batches, each containing approximately 2000 images. Particle picking was performed using well-defined *Tv20S*-MZB particles as templates. 2D classifications were also conducted in four batches, and subsequently, visually well-defined particles were selected (528,679), reclassified, and filtered using both 2D and 3D classification methods. After several rounds of further selection processes, 80,145 particles were retained for the final 3D map generation. The resulting cryo-EM map of *Tv20S* complexed with CP-17 exhibited a final resolution estimate of 2.60 \AA , as determined by GSFSC analysis. An overview of cryo-EM data processing workflow is shown in Supplementary Fig. 10.

Model building and refinement

A high-resolution proteasome structure of *Leishmania tarentolae* (PDB ID: 7ZYJ) was used as an initial template to build the model⁴⁷. The initial model was built by alignment of *Tv20S* the structures predicted by AlphaFold onto the 7ZYJ template. The *Tv20S*-MZB model was fitted to density using ChimeraX⁵¹ and refined by rigid body refinement and real space refinement in Coot 0.9.8.5 EL⁵² and structure optimization using

ISOLDE package⁵³ in ChimeraX⁵⁴. Representative images of the structures and maps were generated using ChimeraX and Pymol. The *Tv20S*-CP-17 structure was refined in a similar manner as the *Tv20S*-MZB structure using the *Tv20S*-MZB complex as a starting model. Local resolution maps for both cryoEM maps were estimated using individual half maps and conducting calculations in Phenix v1.20.1-4487⁵⁵. The data were implemented into *Tv20S*-MZB and *Tv20S*-CP-17 maps and colored according to the local resolution estimates in ChimeraX⁵⁴ (Supplementary Fig. 11). The reported maximum resolution (Supplementary Table 2) for deposited Cryo-EM maps was determined through FSC analysis by applying a tight mask to selected Cryo-EM map, with a threshold of 0.143. The *Tv20S*-MZB structure was deposited to the world protein data bank under the ID number PDB ID: 8OIX and the *Tv20S*-CP-17 structure under PDB ID: 8POT (Supplementary Table 2).

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The atomic coordinates were deposited in the Protein Data Bank (<https://www.rcsb.org>) under the PDB accession codes 8OIX and 8POT. Cryo-EM density maps are available under accession codes EMD-16901 and EMD 17337. Mass spectrometry data is available under accession code PXD051584. Links to the atomic coordinates used in this study: 4R3O, 5LF3, 7AWE, 7PG9, 7ZYJ, 8OIX, 8POT. Source data are provided as a Source Data files. The proteomics data generated in this study are provided as Supplementary Data 1. These raw data are available at the following repositories: FTP link: <ftp://massive.ucsd.edu/v07/MSV000094569/> or ProteomeXchange: PXD051584. Source data are provided with this paper.

References

- Munoz, C., San Francisco, J., Gutierrez, B. & Gonzalez, J. Role of the Ubiquitin-Proteasome systems in the biology and virulence of protozoan parasites. *Biomed. Res. Int.* **2015**, 141526 (2015).
- Edwards, T., Burke, P., Smalley, H. & Hobbs, G. *Trichomonas vaginalis*: Clinical relevance, pathogenicity and diagnosis. *Crit. Rev. Microbiol.* **42**, 406–417 (2016).
- Rowley, J. et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. *Bull. World Health Organ.* **97**, 548–562P (2019).
- Bouchenal, K., Bories, C. & Loiseau, P. M. Strategies for prevention and treatment of *Trichomonas vaginalis* Infections. *Clin. Microbiol. Rev.* **30**, 811–825 (2017).
- Van Gerwen, O. T., Camino, A. F., Sharma, J., Kissinger, P. J. & Muzny, C. A. Epidemiology, natural history, diagnosis, and treatment of *Trichomonas vaginalis* in men. *Clin. Infect. Dis.* **73**, 1119–1124 (2021).
- Alessio, C. & Nyirjesy, P. Management of resistant Trichomoniasis. *Curr. Infect. Dis. Rep.* **21**, 31 (2019).
- Marques-Silva, M., Lisboa, C., Gomes, N. & Rodrigues, A. G. *Trichomonas vaginalis* and growing concern over drug resistance: a systematic review. *J. Eur. Acad. Dermatol. Venereol.* **35**, 2007–2021 (2021).
- Xie, S. C., Dick, L. R., Gould, A., Brand, S. & Tilley, L. The proteasome as a target for protozoan parasites. *Expert Opin. Ther. Targets.* <https://doi.org/10.1080/14728222.2019.1685981> (2019).
- Winzeler, E. A. & Otilie, S. The proteasome as a target: How not tidying up can have toxic consequences for parasitic protozoa. *Proc. Natl Acad. Sci. USA* **116**, 10198–10200 (2019).
- O'Donoghue, A. J. et al. 20S Proteasome as a drug target in *Trichomonas vaginalis*. *Antimicrob. Agents Chemother.* **63**, e00448–19 (2019).

11. Petrin, D., Delgaty, K., Bhatt, R. & Garber, G. Clinical and micro-biological aspects of *Trichomonas vaginalis*. *Clin. Microbiol. Rev.* **11**, 300–317 (1998).
12. Finley, D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. *Annu. Rev. Biochem.* **78**, 477–513 (2009).
13. Collins, G. A. & Goldberg, A. L. The logic of the 26S Proteasome. *Cell* **169**, 792–806 (2017).
14. Lecker, S. H., Goldberg, A. L. & Mitch, W. E. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. *J. Am. Soc. Nephrol.* **17**, 1807–1819 (2006).
15. Majumder, P. & Baumeister, W. Proteasomes: unfoldase-assisted protein degradation machines. *Biol. Chem.* **401**, 183–199 (2019).
16. Budenholzer, L., Cheng, C. L., Li, Y. & Hochstrasser, M. Proteasome structure and assembly. *J. Mol. Biol.* **429**, 3500–3524 (2017).
17. Mao, Y. Structure, dynamics and function of the 26S Proteasome. *Sub-Cell. Biochem.* **96**, 1–151 (2021).
18. Xie, S. C. et al. The structure of the PA28-20S proteasome complex from *Plasmodium falciparum* and implications for proteostasis. *Nat. Microbiol.* **4**, 1990–2000 (2019).
19. Li, H. et al. Structure- and function-based design of *Plasmodium*-selective proteasome inhibitors. *Nature* **530**, 233–236 (2016).
20. Fajtova, P. et al. Development of subunit selective substrates for *Trichomonas vaginalis* proteasome. *bioRxiv*. <https://doi.org/10.1101/2023.04.05.535794> (2023).
21. Zwickl, P., Lottspeich, F. & Baumeister, W. Expression of functional *Thermoplasma acidophilum* proteasomes in *Escherichia coli*. *FEBS Lett.* **312**, 157–160 (1992).
22. Toste Rego, A. & da Fonseca, P. C. A. Characterization of fully recombinant Human 20S and 20S-PA200 proteasome complexes. *Mol. Cell* **76**, 138–147.e135 (2019).
23. Le Tallec, B. et al. 20S proteasome assembly is orchestrated by two of chaperones in yeast distinct pairs and in mammals. *Mol. Cell* **27**, 660–674 (2007).
24. Schnell, H. M., Walsh, R. M., Rawson, S. & Hanna, J. Chaperone-mediated assembly of the proteasome core particle - recent developments and structural insights. *J. Cell Sci.* **135**, jcs259622 (2022).
25. Livneh, I., Cohen-Kaplan, V., Cohen-Rosenzweig, C., Avni, N. & Ciechanover, A. The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death. *Cell Res.* **26**, 869–885 (2016).
26. Huber, E. M. et al. A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome. *Nat. Commun.* **7**, 10900 (2016).
27. Escobar-Henriques, M., Altin, S. & Brave, F. D. Interplay between the Ubiquitin Proteasome system and mitochondria for protein homeostasis. *Curr. Issues Mol. Biol.* **35**, 35–58 (2020).
28. Koga, H., Kaushik, S. & Cuervo, A. M. Protein homeostasis and aging: The importance of exquisite quality control. *Ageing Res. Rev.* **10**, 205–215 (2011).
29. Ito, S. Proteasome Inhibitors for the Treatment of Multiple Myeloma. *Cancers* **12**. <https://doi.org/10.3390/cancers12020265> (2020).
30. LaMonte, G. M. et al. Development of a potent inhibitor of the plasmodium proteasome with reduced mammalian toxicity. *J. Med. Chem.* **60**, 6721–6732 (2017).
31. Almaliti, J. et al. Development of potent and highly selective Epoxyketone-based plasmodium proteasome inhibitors. *Chemistry* **29**, e202203958 (2023).
32. Khare, S. et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. *Nature* **537**, 229–233 (2016).
33. Wyllie, S. et al. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. *Proc. Natl Acad. Sci. USA* **116**, 9318–9323 (2019).
34. Nagle, A. et al. Discovery and characterization of clinical candidate LXE408 as a Kinetoplastid-selective proteasome inhibitor for the treatment of Leishmaniasis. *J. Med. Chem.* **63**, 10773–10781 (2020).
35. Pereira, A. R. et al. The Carmaphycins: New proteasome inhibitors exhibiting an alpha,beta-epoxyketone warhead from a marine cyanobacterium. *Chembiochem* **13**, 810–817 (2012).
36. Bibo-Verdugo, B. et al. The proteasome as a drug target in the metazoan pathogen. *ACS Infect. Dis.* **5**, 1802–1812 (2019).
37. Ishii, A., Matsui, M., Terano, Y. & Miura, Y. Establishment and characterization of a novel human-malignant melanoma cell-line Aki. *Cell Mol. Biol.* **34**, 255–264 (1988).
38. Feling, R. H. et al. Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus *Salinospora*. *Angew. Chem. Int. Ed.* **42**, 355–357 (2003).
39. Roth, P., Mason, W. P., Richardson, P. G. & Weller, M. Proteasome inhibition for the treatment of glioblastoma. *Expert Opin. Investig. Drugs* **29**, 1133–1141 (2020).
40. Di, K. J. et al. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. *Neuro-Oncol.* **18**, 840–848 (2016).
41. Manton, C. A. et al. Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo. *Sci. Rep.* **6**, 18953 (2016).
42. Groll, M., Huber, R. & Potts, B. C. M. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. *J. Am. Chem. Soc.* **128**, 5136–5141 (2006).
43. Hirano, Y. et al. Dissecting beta-ring assembly pathway of the mammalian 20S proteasome. *EMBO J.* **27**, 2204–2213 (2008).
44. Murata, S., Yashiroda, H. & Tanaka, K. Molecular mechanisms of proteasome assembly. *Nat. Rev. Mol. Cell Biol.* **10**, 104–115 (2009).
45. Satoh, T. et al. Molecular and structural basis of the proteasome subunit assembly mechanism mediated by the proteasome-assembling Chaperone PAC3-PAC4 Heterodimer. *Int. J. Mol. Sci.* **20**, 2231 (2019).
46. Velez, B. et al. Mechanism of autocatalytic activation during proteasome assembly. *Nat. Struct. Mol. Biol.* <https://doi.org/10.1038/s41594-024-01262-1> (2024).
47. Koester, D. C. et al. Discovery of Novel Quinoline-based proteasome inhibitors for Human African Trypanosomiasis (HAT). *J. Med. Chem.* <https://doi.org/10.1021/acs.jmedchem.2c00791> (2022).
48. Borissenko, L. & Groll, M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. *Chem. Rev.* **107**, 687–717 (2007).
49. Marques, A. J., Glanemann, C., Ramos, P. C. & Dohmen, R. J. The C-terminal extension of the beta7 subunit and activator complexes stabilize nascent 20 S proteasomes and promote their maturation. *J. Biol. Chem.* **282**, 34869–34876 (2007).
50. Jalovecka, M. et al. Validation of Babesia proteasome as a drug target. *Int J. Parasitol. Drugs Drug Resist.* **8**, 394–402 (2018).
51. Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Sci.* **30**, 70–82 (2021).
52. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta Crystallogr. Sect. D. Biol. Crystallogr.* **66**, 486–501 (2010).
53. Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. *Acta Crystallogr. D.* **74**, 519–530 (2018).
54. Meng, E. C. et al. UCSF ChimeraX: Tools for structure building and analysis. *Protein Sci.* **32**, e4792 (2023).

55. Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. *Acta Crystallogr. D.* **75**, 861–877 (2019).

Acknowledgements

The data was collected at the Umeå Center for Electron Microscopy, a node of the Cryo-EM Swedish National Facility, funded by the Knut and Alice Wallenberg, Family Erling Persson and Kempe Foundations, Sci-LifeLab, Stockholm University and Umeå University. and we thank in particular to Michael Hall, Camilla Holmlund, and Linda Sandblad. We are grateful to Karim Rafie and Lar-Anders Carlson for invaluable help with cryo-EM experiments and data processing. The research was supported by NIH awards AI158612 and AI146387 to AJO, LE, and WHG, and DK120515 to LE. We would like to thank Dr. Samuel A. Myers, La Jolla Institute for Immunology for mass spectrometry support. PF received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No [846688]. This research was funded by the project the National Institute Virology and Bacteriology (Program EXCELES, Project No. LX22NPO5103) - Funded by the European Union - Next Generation EU (awarded E.B.). Academy of Sciences of the Czech Republic, RVO: 61388963, is also acknowledged. BMH was supported in part by the UCSD Graduate Training Program in Cellular and Molecular Pharmacology through an institutional training grant from the National Institute of General Medical Sciences, T32 GM007752. PF would like to acknowledge Milan Fabry for providing advice on cloning and Martin Horn for assistance with enzymatic assays. JA would like to acknowledge the St. Baldrick's Foundation for the International Scholar award 2022–2025 and the deanship of scientific research at the University of Jordan for the scientific leave.

Author contributions

J.S. collected and processed cryo-EM data, J.B., P.F., B.M.H. performed expression and enzyme experiments. Y.M. and L.E. cultured *T. vaginalis* and provided cell lysates, J.A. and W.H.G. designed and synthesized CP-17, P.F., A.J.O. and E.B. conceived the project. J.S., P.F., A.J.O. and E.B. wrote the manuscript. All authors critically reviewed the paper. A.J.O. and E.B. supervised the project. P.F., L.E., W.H.G., A.J.O., and E.B. obtained funding.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-024-53022-w>.

Correspondence and requests for materials should be addressed to Pavla Fajtova, Anthony J. O'Donoghue or Evzen Boura.

Peer review information *Nature Communications* thanks the anonymous reviewers for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024